Picture a retired schoolteacher sitting at her kitchen table with two envelopes in front of her. One is her electricity bill. The other is the receipt from her pharmacy. She cannot pay both this month. She has not been able to for the past several months. So she does what millions of Americans do quietly and without any news coverage: she cuts her pills in half, skips every other dose, and hopes the condition she has managed for a decade does not spiral out of control before her next Social Security payment arrives.
This is not a story from a developing nation without healthcare infrastructure. This is a story happening in the wealthiest country in human history, every single day, across every income level, every age group, and every political affiliation. Prescription drug costs in the United States have reached a point of genuine crisis that transcends partisan debate and demands honest examination. Americans pay more for prescription medications than citizens of any other high-income country in the world. Not slightly more. Dramatically, sometimes shockingly more, for the identical molecules manufactured under equivalent conditions.
The Staggering Scale of the Problem
Prescription drug costs in the United States are not just a personal financial burden. They are a public health crisis with measurable consequences. Research consistently shows that cost-related medication non-adherence, meaning people not taking medications as prescribed because they cannot afford them, is widespread and growing. The Kaiser Family Foundation has found that approximately one in four Americans reports difficulty affording their prescription medications. A similar proportion reports rationing medications, splitting pills, skipping doses, or not filling prescriptions at all because of cost.
The consequences of medication non-adherence driven by cost are not abstract. They are clinical. When a diabetic patient cannot afford insulin, blood sugar becomes uncontrolled, leading to complications including nerve damage, kidney failure, blindness, and cardiovascular disease. When a hypertension patient skips blood pressure medication because of cost, the risk of stroke and heart attack increases substantially. When a psychiatric patient cannot maintain medication because of affordability, mental health crises that lead to emergency department visits, hospitalization, and sometimes suicide become more likely. The human cost of high prescription drug costs is measured in preventable suffering and preventable death.
How Drug Pricing Actually Works: The System Behind the Number
The Absence of Price Regulation: America’s Unique Position
The single most important structural explanation for high prescription drug costs in the United States is one that surprises many people who have not examined it closely: unlike every other high-income country in the world, the United States does not regulate the prices that pharmaceutical manufacturers can charge for their products. In Canada, the Patented Medicine Prices Review Board limits the prices of patented drugs based on comparative international pricing. In Germany, the AMNOG process requires manufacturers to demonstrate added clinical benefit relative to existing treatments, and prices are negotiated based on that demonstrated value. In the United Kingdom, the National Institute for Health and Care Excellence evaluates drugs for cost-effectiveness and recommends pricing accordingly. Japan, France, Australia, and virtually every other wealthy democracy have some form of drug price regulation or negotiation at the government level.
The United States does not. Pharmaceutical manufacturers operating in the U.S. market can set their list prices at whatever level the market will bear, limited only by the willingness of payers to cover the drug and the ability of patients to access alternatives. This pricing freedom, unique in the developed world, is the foundational structural reason why prescription drug costs in the United States are so much higher than elsewhere.
Patent Exclusivity and the Monopoly of Innovation
Patents are the legal mechanism through which pharmaceutical companies receive temporary market exclusivity for new drugs in exchange for public disclosure of the drug’s composition and method of manufacture. In the United States, a new drug patent provides twenty years of exclusivity from the date of filing, and additional regulatory exclusivity periods can extend the period of market protection beyond the patent term. During this exclusivity period, the patent holder is the only legal manufacturer of the drug in the United States, creating a legal monopoly with no competitive pressure to reduce prices.
The monopoly granted by patent exclusivity is not inherently problematic. The patent system exists because pharmaceutical development requires enormous upfront investment in research, clinical trials, regulatory submission, and manufacturing scale-up, and without some period of market exclusivity to recoup those investments, the financial incentive to develop new drugs would be severely reduced. The tension between incentivizing innovation and ensuring affordable access to the fruits of that innovation is genuine and does not have a simple resolution.
But the pharmaceutical industry has developed a range of strategies to extend the effective market exclusivity of profitable drugs well beyond the period that the original innovation-incentive rationale would justify. Evergreening is the practice of making minor modifications to an existing drug, changing the formulation, the dosage, the delivery mechanism, or a metabolite, and obtaining new patents on these modifications that extend the period of market exclusivity. These modifications often provide no clinically meaningful advantage over the original drug. They exist primarily to extend the period during which the manufacturer can charge monopoly prices without generic competition.
The Pharmaceutical Supply Chain: Layers of Cost That Few Understand
Pharmacy Benefit Managers: The Middlemen Who Shape Drug Costs
Between pharmaceutical manufacturers and patients lies a complex supply chain with multiple intermediaries, each of which extracts value from the flow of drug spending. The least understood but most consequential of these intermediaries is the pharmacy benefit manager, or PBM. PBMs are companies hired by insurance plans, employers, and government programs to manage prescription drug benefits on their behalf. They negotiate rebates with manufacturers, design formularies that determine which drugs are covered at what cost-sharing level, process pharmacy claims, and set the reimbursement rates paid to pharmacies.
The three largest PBMs, CVS Caremark, Express Scripts, and OptumRx, together manage prescription drug benefits for the vast majority of insured Americans. Their market concentration gives them significant negotiating power with both manufacturers and pharmacies. But the way their business model is structured creates incentives that do not necessarily align with the interests of patients or payers.
PBMs negotiate rebates from manufacturers in exchange for favorable formulary placement. A drug that pays a larger rebate may receive preferred coverage status over a drug with a lower list price but smaller rebate, even if the lower-priced drug would result in lower total spending. This dynamic has contributed to the inflation of drug list prices: manufacturers can charge higher list prices and offer large rebates to PBMs, while patients whose cost-sharing is based on list price rather than net price pay more. The net price after rebates may be substantially lower than the list price, but patients and small plan sponsors may not benefit from the negotiated rebates in proportion to their drug spending.
The Role of Distributors, Wholesalers, and Pharmacies
Beyond PBMs, the pharmaceutical supply chain includes wholesale drug distributors who purchase drugs from manufacturers and distribute them to pharmacies, hospitals, and other dispensing entities. The three largest drug distributors, McKesson, Cardinal Health, and AmerisourceBergen, together distribute the vast majority of pharmaceuticals in the United States and are among the largest companies in the country by revenue.
Pharmacies, both chain and independent, represent the final point in the supply chain before drugs reach patients. Pharmacy reimbursement rates, set primarily through PBM negotiations, have been a source of significant financial pressure on independent pharmacies in particular, many of which have struggled to remain viable as reimbursement rates have declined relative to their costs. This financial pressure has contributed to pharmacy closures in rural and underserved communities, reducing medication access for populations that already face barriers to healthcare.
Research and Development Costs: The Argument Manufacturers Make
The pharmaceutical industry’s primary justification for high drug prices is the cost of research and development. Developing a new drug from initial discovery through clinical trials and regulatory approval is genuinely expensive and genuinely risky. Industry estimates of the average cost to bring a new drug to market range from $1 billion to $2.6 billion, accounting for the cost of failures. The regulatory pathway requires years of preclinical testing, three phases of clinical trials with growing numbers of participants, and extensive documentation for FDA review. This process takes an average of ten to fifteen years from initial discovery to market approval.
These costs are real. The question is whether they justify the prices charged and whether the relationship between development cost and price is as direct as the industry suggests. Several lines of evidence complicate the industry’s argument. Many of the most expensive drugs were developed with substantial contributions from publicly funded research. The National Institutes of Health has contributed to the development of virtually every top-selling drug over the past several decades, through direct funding of basic research, funding of academic research that identified drug targets, or funding of clinical trials. The public investment in drug development is substantial, yet the public receives no corresponding benefit in the form of price constraints on the resulting products.
The Human Faces of Prescription Drug Costs
Insulin: The Clearest Case Study in Pricing Failure
No drug better illustrates the dysfunction of prescription drug pricing in the United States than insulin. Insulin is not a new drug. It was discovered in 1921 and the discoverers, Canadian researchers Frederick Banting and Charles Best, sold the patent to the University of Toronto for one dollar, explicitly so that the drug would be accessible to all who needed it. For decades, insulin was an inexpensive commodity medication available at modest cost.
Today, the most widely used modern insulin formulations in the United States cost hundreds of dollars per vial, with some patients requiring two or more vials per month for adequate control. Patients without adequate insurance coverage have paid list prices of $300 or more per vial for insulin that costs approximately $3 to $6 to manufacture. The gap between manufacturing cost and patient price for a medication that people with Type 1 diabetes require to survive is not an expression of innovation value. It is an expression of a pricing system without constraints.
Final Thoughts
Prescription drug costs are not a force of nature. They are not an inevitable consequence of the complexity of modern medicine or the genuine risks of pharmaceutical development. They are the accumulated result of specific policy choices made over decades, specific corporate strategies pursued in a regulatory environment that permitted them, and specific power dynamics that have consistently prioritized industry revenue over patient access.
Understanding this is not cause for hopelessness. It is cause for precisely calibrated outrage directed at the right targets. The retired schoolteacher splitting her pills at the kitchen table did not create the system that put her in that position. But the people who design drug pricing policy, who lobby against price negotiation, who structure rebate systems that obscure true costs, and who extend patent protection through incremental modifications did create it. And systems built by human decisions can be rebuilt by better ones.